Compare · ALKS vs LLY
ALKS vs LLY
Side-by-side comparison of Alkermes plc (ALKS) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALKS and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.07T, about 149.4x ALKS ($7.13B).
- Over the past year, ALKS is up 36.7% and LLY is up 50.2% - LLY leads by 13.5 points.
- ALKS has been more active in the news (18 items in the past 4 weeks vs 16 for LLY).
- Both have 25 recent analyst ratings on file.
- Company
- Alkermes plc
- Eli Lilly and Company
- Price
- $42.55-0.58%
- $1161.06+2.49%
- Market cap
- $7.13B
- $1.07T
- 1M return
- +20.16%
- +19.11%
- 1Y return
- +36.68%
- +50.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1991
- News (4w)
- 18
- 16
- Recent ratings
- 25
- 25
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ALKS
- EVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $87,564 worth of Ordinary Shares (2,034 units at $43.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 229,524 units (SEC Form 4)
- Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
- Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- EVP R&D, Chief Medical Officer Hopkinson Craig C. sold $375,044 worth of Ordinary Shares (9,000 units at $41.67) as part of a pre-agreed trading plan and exercised 5,000 units of Ordinary Shares at a strike of $19.34, decreasing direct ownership by 5% to 77,389 units (SEC Form 4)
- VP, Finance (Interim PAO) Parisi Samuel Joseph sold $687,007 worth of Ordinary Shares (16,217 units at $42.36) and exercised 16,217 units of Ordinary Shares at a strike of $19.48 (SEC Form 4)
- Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
- Director Wright Christopher I converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 20% to 27,680 units (SEC Form 4)
- Director Wilson Frank Anders covered exercise/tax liability with 1,475 units of Ordinary Shares and converted options into 6,142 units of Ordinary Shares, increasing direct ownership by 15% to 35,751 units (SEC Form 4)
- Director Snyderman Nancy Lynn Md converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 44% to 15,395 units (SEC Form 4)
- Director Mckeon Brian P converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 14% to 38,536 units (SEC Form 4)
Latest LLY
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial